MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

医学 内科学 共病 糖尿病 骨髓增生异常综合症 人口 骨髓 环境卫生 内分泌学
作者
Massimo Breccia,Vincenzo Federico,Giuseppina Loglisci,Roberto Latagliata,Michelina Santopietro,Adriano Salaroli,Alessandra Serrao,Gioia Colafigli,Agostino Tafuri,Giuliana Alimena
出处
期刊:Blood [Elsevier BV]
卷期号:118 (21): 3793-3793 被引量:1
标识
DOI:10.1182/blood.v118.21.3793.3793
摘要

Abstract Abstract 3793 MDS-specific comorbidity index (MDS-CI) is a score reported by the Pavia group for myelodysplastic syndromes (MDS) patients. This score is a time-dependent index developed for predicting the effect of comorbidities on outcome of these subjects. We applied this score on a total of 450 MDS patients: comorbidities were recorded at the time of diagnosis and considered by medical staff for the analysis. All patients were consecutively diagnosed and followed at our institute in a period between January 1992 and December 2006. Statistical analysis was carried out using SPSS software; survival was defined as time from diagnosis to last contact or death for any cause. Median age of the whole population was 69 years (range 21–88), with a prevalence of male sex (ratio m/f 1.6). Overall, we found the presence of one or more comorbidities in 94% of the examined patients. The most common comorbidities were cardiac disorders observed in 40% of patients, followed by diabetes with organ damage recorded in 22 cases. Application of MDS-CI score identified 300 patients with score 0, 55 patients with score 1, 80 patients with score 2 and 15 patients with score >2. We found significant differences in OS according to MDS-CI stratification: from 38 months for low risk patients (score 0) to 22 months for high-risk patients (score >2, p=0.02). We then evaluated the prognostic effect of MDS-CI on patients stratified according to WPSS prognostic index. WPSS application was possible in 330 of 450 patients who entered the analysis (73%), due to cytogenetic availability of data: we identified 112 patients (34%) with very low/low risk, 137 patients (41.5%) with intermediate risk and 81 patients (24.5%) with high/very high risk. As reported by the Pavia group, we assessed prognostic relevance of comorbidities in very low/low risk WPSS patients, intermediate and high/very high-risk patients. We found in the first category a significant difference in OS stratification: from 48.5 months for patients with score 0 to 20.4 months for patients with score >2 (p=0.002). In WPSS intermediate risk we found similar significant OS difference: from 32.3 months for patients with score 0 to 18.3 months for patients with score 2 (p=0.001). Conversely, we did not find significant differences in WPSS high/very high-risk patients. We also found significant correlations between presence of comorbidities at baseline, as stratified with MDS-CI, and risk of non-leukemic death: from 22% in patients without comorbidities to 75% in patients with score >2 according to MDS-CI (p=0.002). Our analysis showed the efficacy of MDS-CI on a large series of MDS consecutively seen, diagnosed and followed in a single center while strengthening the results reported by the Pavia group: in fact, the value of comorbidities was confirmed in a cohort of patients similar to that observed in the original paper, in terms of median age (69 years in our series vs 66 years in the Pavia series), but with higher percentage of patients with intermediate WPSS risk (41.5% in our series vs 18% in the Pavia population). MDS-CI is a very valid tool capable to differentiate MDS patients with very low/low and intermediate WPSS risk in terms of OS and non-leukemic death risk. Disclosures: Alimena: Novartis: Honoraria; Bristol Myers Squibb: Honoraria.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
凌代萱完成签到 ,获得积分10
刚刚
1秒前
1秒前
mmm完成签到,获得积分20
4秒前
powell应助喜喵喵采纳,获得10
5秒前
高手发布了新的文献求助10
5秒前
6秒前
gsq发布了新的文献求助30
7秒前
8秒前
香蕉妙菱发布了新的文献求助10
9秒前
深情安青应助wwwstt采纳,获得10
10秒前
易酰水烊酸应助苏苏采纳,获得10
11秒前
11秒前
12秒前
英姑应助小刘采纳,获得10
12秒前
李彪发布了新的文献求助30
12秒前
开心每一天完成签到 ,获得积分10
13秒前
星辰大海应助高手采纳,获得10
13秒前
温柔的姿完成签到,获得积分10
14秒前
传奇3应助gj采纳,获得10
19秒前
XYX关闭了XYX文献求助
27秒前
曲奇吐司完成签到,获得积分10
31秒前
FashionBoy应助Sijie采纳,获得10
33秒前
dong应助夏木夏采纳,获得10
34秒前
美好二娘完成签到 ,获得积分10
36秒前
量子星尘发布了新的文献求助10
38秒前
唐慢慢发布了新的文献求助10
38秒前
ding应助猪猪hero采纳,获得10
38秒前
朴素若枫完成签到,获得积分10
39秒前
苏孖完成签到,获得积分10
41秒前
43秒前
44秒前
t团子完成签到,获得积分10
44秒前
潇湘雪月发布了新的文献求助10
45秒前
一枚小豆完成签到,获得积分10
47秒前
hahahah完成签到,获得积分10
48秒前
坦率耳机应助朴素若枫采纳,获得10
49秒前
wucl1990发布了新的文献求助10
49秒前
科研通AI5应助CSPC001采纳,获得10
49秒前
50秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989242
求助须知:如何正确求助?哪些是违规求助? 3531393
关于积分的说明 11253753
捐赠科研通 3270010
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136